title: Glycemic control after addition of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes showing inadequate response to thrice-a-day treatment with α-glucosidase inhibitors.
abstract: OBJECTIVE
  We investigated the effect of addition of alogliptin, while continuing the α-glucosidase inhibitor (αGI) administration at the same or reduced dose, or discontinuing the drug, on the glycemic control in type 2 diabetic patients showing inadequate response to αGI treatment.
  
  
  METHODS
  A prospective, randomized, controlled, multicenter interventional study trial. Subjects were randomly assigned to treatment with alogliptin alone (Intake 0 group), or alogliptin in addition to an αGI administered once-/twice-/thrice-daily (Intake 1, 2 and 3 groups).
  
  
  METHODS
  Changes in glycemic control were measured.
  
  
  RESULTS
  The HbA1c and glycoalbumin levels at 1 and 3 months were significantly lower than the values at the baseline in the Intake 1, 2 and 3 groups, but not the Intake 0 group. The body weight at 3 months was significantly lower than that at the baseline in the Intake 3 group. There were no significant differences in the degree of satisfaction or participating volition recorded, before and after the start of the study treatments.
  
  
  CONCLUSIONS
  Addition of alogliptin to once-/twice-daily administration of an αGI may be effective for obtaining improved glycemic control, without lowering the treatment satisfaction level, in type 2 diabetic patients.
authors.affiliation: Yokohama City University Graduate School of Medicine, Department of Endocrinology and Metabolism , Yokohama , Japan.
authors.forename: Kiyomi
authors.initials: K
authors.lastname: Masuda
authors.forename: Kazutaka
authors.initials: K
authors.lastname: Aoki
authors.forename: Kazunari
authors.initials: K
authors.lastname: Kamiko
authors.forename: Masahiro
authors.initials: M
authors.lastname: Takihata
authors.forename: Yuzuru
authors.initials: Y
authors.lastname: Ito
authors.forename: Mieko
authors.initials: M
authors.lastname: Nagakura
authors.forename: Satsuki
authors.initials: S
authors.lastname: Kawasaki
authors.forename: Noriko
authors.initials: N
authors.lastname: Akema
authors.forename: Maki
authors.initials: M
authors.lastname: Hasegawa
authors.forename: Shigeru
authors.initials: S
authors.lastname: Nakajima
authors.forename: Kazuaki
authors.initials: K
authors.lastname: Shinoda
authors.forename: Shyoken
authors.initials: S
authors.lastname: Toumura
authors.forename: Seishi
authors.initials: S
authors.lastname: Tsunoda
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Enomoto
authors.forename: Hidefumi
authors.initials: H
authors.lastname: Shimotomai
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Terauchi
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006442:Glycated Hemoglobin / Q000378:metabolism; D017127:Glycation End Products, Advanced; D065089:Glycoside Hydrolase Inhibitors; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010880:Piperidines / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D011446:Prospective Studies; D012709:Serum Albumin / Q000378:metabolism; D013997:Time Factors; D016896:Treatment Outcome; D014498:Uracil / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D000093423:Glycated Serum Albumin
chemical_list: D054873:Dipeptidyl-Peptidase IV Inhibitors; D006442:Glycated Hemoglobin; D017127:Glycation End Products, Advanced; D065089:Glycoside Hydrolase Inhibitors; D007004:Hypoglycemic Agents; D010880:Piperidines; D012709:Serum Albumin; D014498:Uracil; D000093423:Glycated Serum Albumin; C517652:hemoglobin A1c protein, human; C520853:alogliptin